Gonorrhoea continues to pose a global public health challenge. In 2020, WHO estimated 82.4 million new infections among adults aged 15–49, with a decade-long global rise in incidence.
Recent years have seen declines in some countries, including the USA and UK, but antimicrobial resistance remains a major barrier to effective treatment. No vaccine for Neisseria gonorrhoeae is available, limiting prevention primarily to behavioral and public health measures.
The Lancet Infectious Diseases report notes that despite observed reductions in certain regions, the overall burden persists and vaccination is not yet an option. The absence of a gonorrhoea vaccine means population protection relies on nonvaccine strategies, while resistance complicates clinical management and containment efforts.
Uncertainty remains regarding the durability of recent regional declines and the long-term trajectory of incidence as resistance evolves.
The Lancet Infectious Diseases published a clinical update in Infectious Disease on 01 Apr 2026.
The item focuses on GoGoVax dispels hopes for gonorrhoea vaccination.
Review the original article for the full source wording and details.